SPRC יתרות המזומנים של החברה SciSparc Corp

SciSparc Ltd focuses on developing cannabinoid treatments for autism therapy, growing independently of external market conditions. The absence of seasonality and the scientific nature of the risks ensure high macro-resilience. Cash volume dynamics confirm liquidity, where the 0.01 indicator determines the status of the capital parameter. Stable demand for the treatment of CNS disorders isolates the company from economic crises.
פילוחי מדדים ואנליטיקה של חברת Clearmind Medicine (SPRC)

For SciSparc Ltd (SPRC), which develops innovative cannabinoid-based drugs, this indicator determines the liquid capital reserve. The metric measures the volume of free funds that guarantee financial stability without external borrowing. By analyzing the company's cash balance, an investor can see the business's current ability to cover operating expenses. Such reserves are critical for the stable funding of leading pharmacologists and their research. A sufficient cash position confirms the viability of the long-term scientific strategy.